In a tightly controlled, clinical research environment, Rychtarik et al. (2000) found that individuals with an alcohol use disorder (AUD) benefited more from inpatient (IP) than outpatient care, if they presented with high alcohol problem severity and/or low cognitive functioning. This study sought to (a) validate and extend these findings within the uncontrolled environment of a community-based treatment center and (b) test whether inpatients had fewer days of involuntary abstinence (e.g., incarcerations), controlling for differences in treatment expectancy across care settings. Clients (N ϭ 176) with an AUD were deterministically assigned to inpatient-need group (needs IP ϭ high severity and/or low cognitive functioning; no need for IP ϭ neither high severity nor low cognitive functioning). Within need group, participants were randomly assigned to 21 days of routine inpatient or outpatient care, plus 6 months of continuing care. Primary outcomes of percentage of days abstinent (PDA), monthly point prevalence abstinence (PPA), and drinks per drinking day (DDD), and the secondary outcome of involuntary abstinence were assessed over 18 months. Among high-severity participants, inpatients significantly reduced DDD, and outpatients did not. Neither problem severity nor cognitive functioning moderated other setting effects. Treatment expectancy, assessed after being informed of scheduled setting, was higher among inpatients than outpatients. High-expectancy inpatients maintained the highest PDA throughout follow-up, had the highest PPA for most of follow-up, and delayed peak prevalence of involuntary abstinence by 6 months. In sum, the Alcohol Problem Severity ϫ Setting interaction on DDD appears robust. The potential moderating role of expectancy will warrant further study.
Only 10% of those in treatment for a substance use disorder (SUD) in the United States are now treated in nonhospital residential (9%) or hospital-based inpatient (1%) programs (Substance Abuse and Mental Health Services Administration, 2014) . The limited availability of residential or inpatient care for SUD today is in marked contrast to practices 30 years ago, when treatment occurred almost exclusively in the inpatient setting. This near universal move to outpatient treatment has largely been driven by managed care and by research that found little or no difference in outcomes between the two settings. Though outpatient treatment is likely to remain dominant for the foreseeable future, recent reviews of this research area suggest that this trend may now have gone too far (Finney, Moos, & Wilbourne, 2014; Reif et al., 2014) , with inpatient treatment becoming inaccessible to some who could potentially benefit most from it. In particular, these reviews suggest that individuals with higher alcohol/drug problem severity benefit more from inpatient than outpatient care. However, the size of these matching effects and the level of severity at which inpatient treatment should be considered remain unclear, leading Finney et al. (2014) to emphasize the need to validate specific placement criteria for allocating individuals with SUDs to different clinical care settings (inpatient vs. outpatient).
In a tightly controlled study of matching clients to inpatient versus outpatient care, Rychtarik et al. (2000) found that individuals with more severe alcohol problems achieved a higher percentage of days abstinent (PDA) and drank fewer drinks per drinking day (DDD) with inpatient than outpatient care, an advantage that persisted throughout an 18-month observation period (i.e., during 6 months of continuing outpatient care for both conditions plus 12 months of follow-up). Independent of this finding, exploratory analyses of five other potential setting moderators (motivation, self-efficacy, social support for drinking, psychiatric severity, and cognitive functioning) found that only cognitive functioning moderated setting effects. Those low in cognitive functioning achieved higher PDA in inpatient than outpatient treatment throughout the 18 months. Alcohol problem severity and cognitive functioning cut points were then developed to better guide setting-placement decisions. Yet, Rychtarik et al. conducted their study in a clinical research center environment, standardized treatment content, controlled for clinical staff effects, and recruited by advertising. Therefore, the question remains whether the effects observed, their size, and the cut points developed are equally valid among clients presenting for treatment in the real-world environment of a community treatment program.
The primary aim of the current study, therefore, was to test whether the treatment-matching effects observed in Rychtarik et al. (2000) on the longitudinal trajectories of alcohol-related outcomes could be validated within the uncontrolled environment of a large, communitybased, chemical-dependency-treatment program. Clients were prospectively matched or mismatched to inpatient or outpatient treatment based upon the respective upper and lower cut points established in the earlier study for problem severity and cognitive functioning. Rychtarik et al. found similar matching effects, regardless of outpatient intensity; outpatient intensity in the current study was therefore made comparable to less intense, standard care. Of note, cognitive functioning in the prior study was measured at the end of the primary treatment phase, whereas in the current study it was measured pretreatment, making it a potentially more useful measure for treatment planning. In addition, data analyses on PDA and DDD were updated to reflect more contemporary approaches to statistical modeling.
Rychtarik et al. also found fewer involuntary abstinent days among inpatients than outpatients across the entire 18-month observation period, and this effect was not moderated by alcohol involvement or cognitive functioning. An involuntary abstinent day is a day on which drinking was restricted due to hospitalization, residential treatment, or incarceration. Hence, involuntary abstinence serves as a measure of posttreatment severe negative consequences associated with health care and criminal justice utilization. A voluntary abstinent day, on the other hand, is defined as an abstinent day on which the client's drinking was not restricted by hospitalization, residential treatment, or incarceration. Following the methods of the earlier study, the current study used voluntary abstinent days and voluntary abstinence as the primary abstinence-related measures. Secondary and tertiary aims, respectively, assessed the replicability of the involuntary abstinence setting effect and, in the absence of a moderation effect, examined any main effects of setting and Setting ϫ Time interactions.
Method Participants
Participants were 176 clients presenting for treatment of alcohol use disorder (AUD) from July 2003 through September 2006 in the outpatient and inpatient medical detoxification programs of the Division of Chemical Dependency of a large, community-based health care network in the same geographical catchment area as the prior study. Eligible participants had to (a) be at least 18 years of age; (b) have drank alcoholic beverages within the last 90 days; (c) have a current address (not homeless); (d) be free of legal stipulations that would affect treatment decisions; (e) not have received treatment for substance misuse within the last 30 days; (f) have a last 3 months Alcohol Use Disorders Identification Test (AUDIT; Babor, de la Fuente, Saunders, & Grant, 1989 ) score Ն10; and (g) have a primary alcohol, or alcohol and other drug problem as assessed by clinical staff. See Table 1 for sample characteristics. The study protocol was reviewed and approved by the University at Buffalo Institutional Review Board prior to implementation.
Procedure
Outpatient treatment staff performed a brief, cursory prescreening for study eligibility and interest as part of the agency's own intake process. Those preliminarily eligible, interested, and willing to consider randomization to treatment setting then completed a full screening interview by on-site research staff; detoxification clients completed the full screening close to discharge. Eligible and consenting individuals subsequently participated in a pretreatment assessment that included measures of motivation, pretreatment drinking, involuntary abstinence, problem severity, and cognitive functioning. To aid the randomization process, results were used to create a presumed inpatient-need category assignment (needs inpatient ϭ high severity and/or low cognitive function; no need for inpatient ϭ neither high severity nor low cognitive functioning) using the Rychtarik et al. (2000) cut points. An urn randomization algorithm then randomly assigned participants within need category to their primary treatment, consisting of 21 days of either inpatient or outpatient care; the algorithm balanced settings within need category on race (White, non-White), gender (male, female), marital status (married: yes, no), prior SUD treatment (yes, no), and incarceration history (yes, no). On completion of the 21-day treatment period, all participants received an additional 6 months of outpatient continuing care.
Participants completed an in-person assessment at the end of the 21-day primary treatment period; follow-up phone assessments at 3, 9, and 15 months post primary treatment; and in-person assessments at 6, 12, and 18 months. All study follow-ups were conducted in the period from November 2003 through April 2008. Except for pretreatment assessment of participants in the detoxification unit just prior to discharge, all assessments occurred at a research location separate from the treatment sites. Research staff blind to participants' setting assignment conducted all assessments. The Consort diagram is presented in Figure 1 .
Treatment Settings
Inpatient treatment. Participants assigned to inpatient treatment were scheduled for 21 days of care in the agency's 20-bed inpatient treatment program located in the health care network's large urban medical center. Following admission, clients met individually with their counselors on the day of admission, and approximately twice a week thereafter. They also attended various program-based education and specialized therapy groups, AlcoholThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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ics Anonymous/Narcotics Anonymous (AA/NA) meetings, and other services provided by the medical center, as appropriate. On completion of inpatient care, they were allowed 24 sessions of continuing outpatient care over the subsequent 6 months. Outpatient treatment. Participants assigned to outpatient treatment could attend up to 30 sessions over approximately 7 months (21 days of primary treatment; 6 months of continuing care). Treatment occurred in either the outpatient clinic where originally screened or, if screened in the detoxification unit, the clinic most convenient for the participant. The primary counselor determined the frequency and mix of the sessions (i.e., individual, family, specialty group, etc.) on the basis of the client's need, although the recommended schedule was six sessions over the course of the 21-day primary treatment period and 24 sessions during continuing care. Weekday, evening, or weekend AA/NA meetings also were available but did not count toward the session total.
Treatment Orientation
The program coordinator of each setting was administered the Drug and Alcohol Treatment Program Inventory (DATPI; Swindle, Peterson, Paradise, & Moos, 1995) prior to study initiation. The DATPI measures the degree to which goals and activities related to eight specific treatment orientations are similar to those used in the respondent's program. The inpatient (IP) and outpatient (OP) coordinators' DATPI subscale scores (possible score range 0 -24; higher scores represent higher use of the approach) were as follows: AA/12 step (IP ϭ 14; OP ϭ 14), cognitive-behavioral (IP ϭ 20; OP ϭ 21), insight/psychodynamic (IP ϭ 18; OP ϭ 17), marital/family (IP ϭ 17; OP ϭ 13), therapeutic community (IP ϭ 14; OP ϭ 10), rehabilitation/vocational (IP ϭ 3; OP ϭ 18), dual diagnosis (IP ϭ 15; OP ϭ 15), and medical (IP ϭ 19; OP ϭ 19). A cognitive- e Percentage of participants totally abstinent in any one month across the 12 months pretreatment (months in which the participant was restricted from drinking on all days were excluded from these analyses).
f Number of standard drinks consumed on days the participant was drinking in the pretreatment months.
g Percentage of days in any pretreatment month in which the participant's drinking was restricted due to hospitalization, residential treatment, or incarceration.
h Percentage of participants with at least 1 restricted-drinking day in a pretreatment month.
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behavioral approach appeared slightly favored in both settings, but an overall eclectic mix was present in each. Vocational rehabilitation services, however, were markedly higher in outpatient relative to inpatient care.
Staffing and Clinical Management
Agency clinical staff at the respective settings provided all care; the primary clinician assigned to provide and coordinate participant care was determined by the respective program's existing staff assignment procedure. A quasi-managed care model then insured that study time and session limits were maintained. Specifically, the primary clinician received the participant's planned completion date, and the number of days and sessions allowed. Research staff then carefully monitored treatment to insure compliance, and provided clinical staff with notices when a client was reaching study-defined limits. The primary clinician could request additional days/sessions under predefined criteria (e.g., acute suicidal ideation, deterioration). Such requests were reviewed by the study's Clinical Care Committee, which could approve a specific amount of additional treatment, or recommend an alternative approach for dealing with the participant's issue. The study paid for all study care not covered by third-party payers.
Measures
Alcohol involvement and cutpoint. Raw scores Ն30 on the Alcohol Involvement Scale (AIS; range ϭ 0 -68) of the Alcohol Use Inventory (AUI; Horn, Wanberg, & Foster, 1990 ) defined a need for inpatient treatment; lower scores defined no need for inpatient treatment. The AIS has good internal consistency (.93) and construct and criterion validity (Horn et al., 1990; Skinner & Allen, 1983 ). Higher scores represent greater obsession with drinking, sustained drinking, perceptual withdrawal, somatic withdrawal, social role maladaptation, and loss of control of behavior when drinking. Derived by Rychtarik et al. (2000) , the cutpoint is at the 35th percentile of AIS norms for AUD populations, and corresponds to the 44th percentile of the current sample.
Cognitive functioning and cutpoint. A correct response score Ͻ42 on the Symbol Digit Modalities Test (SDMT; Smith, 1982 ; range ϭ 0 -90) defined low functioning and need for inpatient treatment; scores Ն42 were classified as high functioning. Derived by Rychtarik et al. (2000) , the cutpoint is at the 45th percentile of this sample; the 19th and 36th percentiles of Project MATCH outpatient and aftercare clients, respectively (Bates, Pawlak, Tonigan, & Buckman, 2006) , and the third percentile of a community sample of males in the participants' age range (Jorm, Anstey, Christensen, & Rodgers, 2004) .
Treatment expectancies. A 6-item, Feelings About Your Scheduled Treatment Scale was administered immediately after participants were informed of their treatment setting assignment, but before treatment initiation. On this measure, developed inhouse by Rychtarik et al. (2000) , participants privately rated their scheduled treatment on a 10-point scale ranging from 1 (not at all) to 10 (extremely) with respect to its reasonableness, their confidence that it will be helpful, their confidence in recommending it to a friend, its similarity to that expected, the expected ease of participating, and their overall satisfaction with the treatment as scheduled. Internal consistency was .87. All staff was blind to expectancy level.
Motivational readiness to change. The University of Rhode Island Change Assessment Scale (McConnaughy, Prochaska, & Velicer, 1983 ) was used to derive a composite readiness score (Project MATCH Research Group, 1997; range ϭ Ϫ2 to 14).
Setting preference. A single-item, administered at the post primary treatment point, assessed the participant's preference for the alternate setting from that assigned on a 6-point scale (1 ϭ There is no way I would have participated in [the alternate setting] even if scheduled; 6 ϭ I very much wanted to receive the [the alternate setting], and I definitely would have gone).
Primary drinking outcomes. The primary outcomes were (a) percentage of voluntary abstinent days (PDA) per month, that is excluding days in which a client was involuntarily detained; (b) monthly point prevalence abstinence (PPA), representing complete abstinence (yes/no) on all unrestricted days of a month; and (c) standard drinks consumed on a drinking day (DDD). PDA and DDD, representing both frequency and intensity drinking measures, respectively, have commonly been used as AUD primary treatment outcomes (e.g., Project MATCH Research Group, 1997), and were the primary, predefined outcomes of Rychtarik et al. (2000) . Though PPA typically has not been reported and was not analyzed by Rychtarik et al. (2000) , we included it among our primary outcomes, as it is the first step in, and integrally related to, the more contemporary twopart DDD analysis model used in the current study (see Data Analyses section). As clients had limited to no access to drinking during days spent hospitalized, in residential treatment, or Figure 1 . Consort diagram. Over a 39-month recruitment period, approximately 8,604 cursory prescreenings were conducted in the outpatient and detoxification programs, combined; 3,842 (45%) of these preliminarily met basic eligibility requirements; 533 (14%) of the latter agreed to a full screening interview; 491 (92%) completed it. AUDIT ϭ Alcohol Use Disorders Identification Test. This document is copyrighted by the American Psychological Association or one of its allied publishers.
being incarcerated, complete voluntary abstinence in any 30-day observation period (PDA ϭ 100) was equivalent to monthly abstinence in the dataset (PPA ϭ 1). All of these measures were derived from the Timeline Followback (TLFB; Sobell & Sobell, 1992) , a self-report technique for determining alcohol and substance use, administered monthly for all 12 months pretreatment, once at the end of the 21-day primary treatment period, and with quarterly frequency across 18 months of follow-up. Alternate PDA and PPA measures were also derived for alcohol and other drug use combined. Study findings for these two variables closely mirrored those for alcohol alone and, therefore, are not reported separately here. Secondary involuntary abstinence outcome. The monthly point prevalence of involuntary abstinence (i.e., of experiencing at least one day in any 30-day period in which the opportunity to drink was restricted due to hospital admission, inpatient or residential treatment, or incarceration) also was derived from the TLFB.
Blood biochemistry. Elevations in the serum transferin protein, carbohydrate deficient transferrin (%CDT; cut score set at 2.6% for both genders), and the liver enzyme, ␥-glutamyl transferase (GGT; elevation level determined using laboratory-specific, gender-based cut-scores) were measured at in-person assessments to check on the degree of accuracy of self-reported heavy drinking (Anton, Lieber, Tabakoff, & the CDTect Study Group, 2002) . A heavy-drinking blood marker index was coded as negative (no elevated test) or positive (elevated CDT and/or GGT).
Statistical Power
The current study was powered to detect Setting ϫ Alcohol Involvement and Setting ϫ Cognitive Functioning interaction effects on percentage of voluntary abstinence days averaged across the first 12 months of follow-up. Power calculations used residual covariance matrices from arcsine-square-root transformed PDA data from Rychtarik et al. (2000) analyzed using random-intercept normal linear models. Regression models included the following variables: baseline voluntary abstinent days, time, setting (inpatient vs. outpatient), moderator (i.e., alcohol involvement or cognitive functioning), Setting ϫ Time and Setting ϫ Moderator interaction. Nondifferential attrition by setting was set at 3% per quarter of follow-up.
On the basis of Hedeker, Gibbons, and Waternaux (1999) and using Cohen's (1988) effect-size nomenclature, a sample size of 166 (83 per setting) at end of 12-month follow-up was needed to achieve at least 80% power for detecting the small-to-moderate Setting ϫ Alcohol Involvement (d ϭ 0.36) and moderate Setting ϫ Cognitive Functioning interactions (d ϭ 0.47) observed by Rychtarik et al. (2000) .
Data Analyses
Generalized linear regression models with canonical link functions were used to analyze the monthly longitudinal trajectories of each outcome of interest across the 18 months. Generalized estimating equations (GEE) with participant ID as the cluster identifier and a working independence correlation matrix were used to account for within-subject correlations across time points. All GEE computations were implemented using the correlatedData library of Splus 8.2 (TIBCO Software, Inc., 2010). Preliminary analyses indicated that assigned treatment outcome expectancies differed significantly between settings, with inpatients expressing higher confidence in their scheduled treatment than outpatients (see Table  1 ). To preclude the possibility that expectancy effects could confound setting effects on drinking outcomes, expectancy terms were added to all models, including main effects and two-way interactions with alcohol involvement, cognitive functioning, and time. Expectancy ϫ Setting interactions were also added to all models, so as to explore whether participants with high outcome expectancy for their assigned treatment setting performed better in inpatient relative to outpatient care.
The initial model specification explored treatment setting effects on the longitudinal trajectories by randomized (i.e., alcohol involvement and cognitive functioning) and nonrandomized (i.e., treatment expectancy) moderators and included recruitment setting (i.e., outpatient clinic vs. detoxification unit). This model was simplified using backward elimination, while ensuring that no lower-order terms were deleted, if higher order terms were statistically significant at the ␣ ϭ .05 level. Model findings were adjusted for 12-month pretreatment values of the outcome via regression modeling, and for differences in exposure through the use of an offset. Time was coded as 0 to 17 months since the first follow-up; cognitive functioning was coded as 0 ϭ low (SDMT Ͻ 42) versus 1 ϭ high (SDMT Ն 42); alcohol involvement was coded as 0 ϭ low (AUI Ͻ 30) versus 1 ϭ high (AUI Ն 30); baseline treatment expectancy was centered at the mean, and scaled by the distance between the mean (M ϭ 8) and the maximum expectancy (Max ϭ 10); baseline PDA was transformed to the logit scale, centered by the median, and scaled by the difference between the median (logit 0.21) and the third quartile (logit 0.56); baseline DDD were log-transformed, centered by the median, and scaled by the difference between the median (ln 12) and the third quartile (ln 16). Outcome-specific information is given in the following text.
Percentage of voluntary abstinence days per month (PDA). Logistic regression was used to estimate the proportion of voluntary abstinent days per 30-day observation period during followup, controlling for PDA differences at baseline. Days with drinking access were adjusted on a monthly basis for the number of days participants spent in restricted status, the modeled response being (number of voluntary days abstinent)/(30-involuntary abstinent days). An overdispersed binomial model was used to account for within-subject correlations in daily abstinence outcomes measured during the same month.
Monthly point prevalence abstinence (PPA) and drinks per drinking day (DDD). In this two-part hurdle model (Atkins, Baldwin, Zheng, Gallop, & Neighbors, 2013; Olsen & Schafer, 2001) , we first estimated the probability of complete abstinence during each month of follow-up using logistic regression for Bernoulli outcomes. We then estimated DDD on a monthly basis for participants who failed to be completely abstinent during the month (PPA ϭ 0), controlling for differences in baseline DDD. The total amount drank per month was used as the outcome, with the number of actual drinking days per month used as an offset. An overdispersed Poisson model was used to account for withinsubject correlations in daily drinking outcomes measured during the same month. Although a zero-truncated Poisson distribution would have been more appropriate for our strictly positive DDD This document is copyrighted by the American Psychological Association or one of its allied publishers.
outcome, observed daily drinking rates were high enough to make such a correction unnecessary. The above analyses offer advances over the linear mixed effects models employed by Rychtarik et al. (2000) . In that study, DDD was treated as a continuous measure, with abstinent days coded 0, and then arcsine square root transformed. The inclusion of 0 DDD, however, underestimates actual DDD, and results in a positively skewed distribution with a mass at the origin that violates distributional assumptions of the normal linear mixed models, even after a normalizing transformation. In addition, this approach conflates two separate distributions represented in monthly DDD data (a) the zero-nonzero distribution representing abstinence versus drinking in a given month-PPA in the current study and (b) the amount of alcohol consumed when there is drinking (DDD), each of which could be differentially influenced by the moderator variables under study. The two-part hurdle model employed in this study allows for separately analyzing these two distributions, and, in conjunction with PDA analyses, provides a more complete picture of participants' abstinence and drinking intensity on drinking days.
Supplemental analyses. The two-part model has been recently criticized by Liu, Strawderman, Johnson, and O'Quigley (2016) for ignoring a possible dependence of DDD on PDA, as subjects more likely to drink on a given day (i.e., those with lower PDA) are also more likely to consume larger amounts of alcohol (i.e., to have higher DDD). For this reason, setting effects on DDD may partly reflect setting effects on PDA. To ensure that our DDD analyses capture direct setting effects not mediated via effects on PDA, we also ran supplementary analyses with logit PDA as an additional model covariate. Also, when Alcohol Involvement ϫ Setting or Cognitive Functioning ϫ Setting interactions were not supported based upon dichotomization of the AIS and SDMT scales at cutoffs previously established in a clinical research setting by Rychtarik et al. (2000) , continuous AIS and SDMT scores were substituted instead, and the resulting interactions assessed in terms of magnitude and significance. Similarly, when an a priori interaction effect was supported for the dichotomous AIS and SDMT scales, sensitivity analyses were conducted to determine whether alternate cutoffs might have been more appropriate for this sample.
Separate, longitudinal logistic regression models estimated using GEE methods examined the relationship between the blood index and each of PDA, PPA, and DDD in the last 30 days of the 6-, 12-, and 18-month follow-up periods. The interval in days between a period's end and blood testing was dichotomized at the median of 18 days and entered in the regression model as a moderator of the association between objective and self-reported drinking measures because the blood tests more accurately reflect recent drinking. Only for PDA did testing interval moderate the relationship (shorter interval ϭ greater association). Hence, the PDA-blood index relationship reported from the model is for assessments completed within 18 days. The correspondence between participant and collateral reports on drinking measures was not evaluated because of a large amount of collateral report uncertainty. The percentage agreement of participant-collateral reports on the point prevalence of involuntary abstinence was calculated at the pair level across all 18 follow-up months and summarized via sample tertiles (median and interquartile range).
Pearson correlation assessed the relationship between expectancy and motivation; Spearman correlations examined expectancy associations with preference and number of continuing care sessions attended.
Results
Figure 1 provides participant flow, treatment participation, and research follow-up rates. Table 1 provides baseline characteristics by setting condition. Stratified randomization was successful in achieving balance between the settings (see Table 1 ). Overall, 133 were found to be in need of inpatient treatment; 43 as having no need for it, an approximate 3:1 ratio that did not differ significantly between conditions, and was comparable to the approximate 3.7:1 ratio in Rychtarik et al. (2000) . Following randomization, inpatients reported significantly higher expectancies (M ϭ 8.29, SD ϭ 1.46) than outpatients (M ϭ 7.72, SD ϭ 2.05; see Table 1 ). Still, expectancies showed substantial overlap across assigned treatment setting, with 98% of inpatients and 90% of outpatients having scores in the 5 to 10 range.
The significance of Setting ϫ Moderator interaction terms is reported in the text. To facilitate interpretation of interactions found significant, Table 2 presents our final models for both primary and secondary outcomes, as applied separately to inpatient and outpatient settings. In this way, the table allows one to examine (a) differences in the level of influence of a parameter (e.g., alcohol involvement) depending on the setting and (b) setting differences at different parameter levels. For example, a replication of the Rychtarik et al. (2000) Setting ϫ Alcohol Involvement interaction on PDA would be exemplified in Table  2 by (a) a nonsignificant effect of alcohol involvement in the inpatient setting but a significant effect in the outpatient setting and (b) significant setting effects in both inpatient and outpatient columns at high, but not at low, alcohol involvement levels. If the Setting ϫ Alcohol Involvement interaction was not significant, and a main effect of alcohol involvement also did not contribute significantly to the model, alcohol involvement would not be retained in the model and would not appear in the Tabled PDA results.
Did Alcohol Involvement and Cognitive Functioning Moderate Setting Effects?
PDA. Neither alcohol involvement nor cognitive functioning significantly moderated setting effects on PDA trajectories. Supplemental analyses also failed to find significant moderation effects using continuous measures of the moderators.
PPA and DDD. Cognitive functioning and alcohol involvement also failed to moderate monthly PPA rates. Supplemental analyses based on continuous measures did not change this finding. However, consistent with Rychtarik et al. (2000) , a significant Setting ϫ Alcohol Involvement interaction (p ϭ .007) did emerge for DDD. Expressed as a drinking rate ratio (RR), among those with higher alcohol involvement, the rate of drinking on a drinking day was 1.61, 95% CI [1.25, 2.07] times higher among outpatients than inpatients; whereas among lower involvement participants the drinking rate of outpatients was not significantly different from inpatients (RR ϭ .85, 95% CI [.58, 1.26] ). To better understand the magnitude of these differences, we note that model intercepts in Table 2 show DDD at follow-up for typical study participants consuming approximately 12 DDD at baseline. Large drinking reductions were observed among lowinvolvement participants, whether as an inpatient (M ϭ 7.92, 95% CI This document is copyrighted by the American Psychological Association or one of its allied publishers.
[ [10.20, 13.94] ). These protective effects of inpatient care persisted across the follow-up period (see Figure 2A) .
Supplemental DDD analyses.
Adding logit PDA as an additional covariate in the DDD model revealed a negative, but not statistically significant, association (p ϭ .45) that failed to deflate the Setting ϫ Alcohol Involvement interaction. Further, detailed interaction probing revealed that the largest interaction effect on DDD did indeed occur at the AIS cutpoint of 30, as derived in the previous study. Note. OR ϭ odds ratio; RR ϭ rate ratio; PDA ϭ percentage of abstinent days per month; Expectancy ϭ mean item score of the Feelings About Your Scheduled Treatment Questionnaire; Voluntary PPA ϭ monthly point-prevalence of complete voluntary abstinence; DDD ϭ monthly standard drinks consumed on a drinking day (log-transformed); Involuntary PPA ϭ monthly point-prevalence of no involuntary abstinence (hospitalization, inpatient treatment, incarcerations; any ϭ 0, none ϭ 1); Alcohol involvement measured via Alcohol Involvement Scale (low: Ͻ30; high: Ն30). a Setting coding: 0 ϭ inpatient, 1 ϭ outpatient. b Setting coding: 0 ϭ outpatient, 1 ϭ inpatient. c Below each outcome variable we provide the reference value for model covariates other than time. Time is coded 0 to 17 months since the first follow-up month. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Did Outcome Expectancies Contribute to the Analysis Models?
PDA. A significant Setting ϫ Expectancy interaction (p Ͻ .001) emerged, such that the benefit of inpatient over outpatient was nearly two and a half times stronger among high versus mean expectancy participants throughout follow-up (OR ϭ 2.48, 95% CI [1.42, 4.22]). Interaction probing over the full range of expectancy scores revealed that inpatients had higher PDA than outpatients at the first month of follow-up for scores above 6.2, representing 85% of the sample. The inpatient benefit attained statistical significance for scores above 7.5, representing 69% of the sample. Setting also interacted with time, such that inpatient PDA rates decreased during early follow-up and then rebounded, while outpatient rates rose steadily, but at a nonsignificant pace. Figure 2B shows the combined effects of the above Setting ϫ Expectancy and Setting ϫ Time relationships for participants with median baseline PDA of 21% at mean (M ϭ 8) and high (Max ϭ 10) expectancy levels. As shown, large differences favoring meanexpectancy inpatients at Month 1 (OR ϭ 3.40, 95% CI [1.72, 6.72 PPA and DDD. A significant Setting ϫ Expectancy (p ϭ .021) interaction also emerged on monthly PPA, with inpatient setting effects twice as strong across time among high versus mean expectancy participants (OR ϭ 2.02, 95% CI [1.11, 3.66] ). Paralleling our PDA findings, Figure 2C shows that inpatients with high treatment expectancy were more likely to exhibit periods of sustained abstinence throughout follow-up than outpatients. For mean-expectancy participants, the odds of abstinence converged quite rapidly over time across treatment settings, with inpatients' odds of abstinence almost twice that for outpatients at Table 2 models the probability of experiencing no involuntary abstinent days during any 30-day period during follow-up. Overlaying a quadratic time effect (p Ͻ .008), a significant Setting ϫ Expectancy ϫ Linear Time interaction (p ϭ .027) was detected, such that expectancy moderated the linear time slope among inpatients (p ϭ .014), but not outpatients (p ϭ .653). Figure 3 plots this effect on the prevalence of any involuntary abstinence. Trajectories among high and low expectancy outpatients are similar; but, among inpatients, high versus mean expectancy lowered the This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
prevalence initially and delayed the peak prevalence by 6 months (i.e., from Month 10 to Month 16).
Did Blood Chemistry and Collateral Reports Agree With Self-Reported Alcohol Measures?
Considerable agreement was observed between 30-day selfreported outcomes and blood chemistry assessments. Among 144 participants with such assessments, the odds of a negative blood index doubled with each 10% increase in PDA (OR ϭ 2.00, 95% CI [1.48, 2.70]); quadrupled with 30-day PPA (OR ϭ 4.09, 95% CI [2. 43, 6 .91]); and decreased by 6% per DDD, (OR ϭ .94, 95% CI [.92, .97] ). Median 30-day participantcollateral agreement on point prevalence of involuntary abstinence (N ϭ 160) was 94% (Q1 ϭ 83%; Q3 ϭ 100%).
Discussion
Two key questions arise when considering the relative benefits of inpatient versus outpatient care. In the following text we discuss these questions in the context of the current study, and the extent to which they are informed by the study results.
Does Inpatient Treatment Produce Better Alcohol Treatment Outcomes Than Outpatient Treatment for All Comers, and, If so, How Big Is the Advantage?
Though only a tertiary focus of the current study, the significant Setting ϫ Linear Time and Setting ϫ Quadratic Time interactions for PPA and PDA, respectively, are consistent with findings of a meta-analysis suggesting an initial, but decreasing benefit of inpatient over outpatient care in the early months of follow-up . In this study, however, the effect appeared stronger than that previously reported. At mean expectancy levels, the advantage of inpatient treatment for PDA was quite large (OR ϭ 3.40) in the first month posttreatment, but was halved by Month 6 (OR ϭ 1.58). For PPA, the advantage for inpatients was not as large (OR ϭ 1.89) at Month 1 and was attenuated further by Month 6 (OR ϭ 1.47). These results highlight the importance of frequent measurement for assessing time trends in outcome research. This study did not evaluate potential mediators of these effects. Specifically, the mechanism through which individuals treated in the inpatient setting achieve better abstinence outcomes, at least initially, is unclear, as are the reasons that this relative benefit is not sustained across time. Finney, Hahn, and Moos (1996) have hypothesized potential mechanisms of the inpatient effect (e.g., the inpatient respite from drinking and stressors), but these were not evaluated in this randomized trial. Identifying mediators of these effects may lead to improvements in both inpatient and outpatient care.
Does Inpatient Treatment Produce Better Alcohol Treatment Outcomes Than Outpatient Treatment Among Identifiable Subgroups of Clients and, If so, How Big Is the Advantage?
This study partially validated, in an uncontrolled community treatment environment, the Rychtarik et al. (2000) finding that individuals with higher levels of alcohol problem severity benefit more from inpatient than outpatient care. However, the replicated finding was limited to a Setting ϫ Alcohol Involvement interaction on DDD. Namely, inpatient treatment significantly reduced DDD among participants at or above the severity cutpoint, whereas outpatient treatment did not. This specific finding appears to be a robust interaction effect that generalizes across both research and clinical environments. However, contrary to Rychtarik et al., neither problem severity nor cognitive functioning moderated setting effects on abstinence.
Noteworthy, though serendipitous, findings indicated that treatment expectancies were higher among inpatients than outpatients, and that these expectancies moderated setting effects, being positively prognostic of PDA and PPA among inpatients, but not outpatients. The result was markedly higher and sustained PDA and PPA among high expectancy inpatients, but not outpatients. Expectancies also moderated setting effects on the incidence of hospitalization, incarceration, or residential treatment, with high expectancy appearing to delay the onset of such involuntary abstinence among inpatients but not outpatients. Expectancies have long been known to influence outcomes in psychological treatments, and such effects can be quite large and robust (e.g., Greenberg, Constantino, & Bruce, 2006) . But, expectancy effects typically have not been assessed in AUD outcome research (Raylu & Kaur, 2012) . The current results suggest that, at least under certain as yet unspecified conditions, expectancy may significantly influence AUD outcomes, as well. However, whether outcome expectancies could be useful in clinical, level-of-care decision making is not known. The expectancy assessment in this study occurred only after the individual knew of his or her setting assignment, not before, as would be required for making placement decisions. Also, as in most expectancy research, the assessment relied on a not-widely studied expectancy measure (Younger, Gandhi, Hubbard, & Mackey, 2012) . Using this same measure, Rychtarik et al. (2000) found no main expectancy effect and did not examine expectancy moderation effects. Future research is needed that implements a more clinically relevant expectancy assessment, before recommendations can be made as to expectancy's clinical value in level of care decision making. This document is copyrighted by the American Psychological Association or one of its allied publishers.
This report does not address a third key question in this area of research. That is, whether the initial, though decreasing benefits from inpatient treatment and the reduction in the rate of drinking among high involvement inpatients versus outpatients outweigh the increased costs of inpatient care. This report did not examine the relative cost-effectiveness of the two treatment settings, nor did it examine any cost savings of placing individuals with higher severity AUDs in inpatient versus outpatient care. Importantly, inpatient treatment in this study was provided in a medical facility, where treatment costs would be expected to be higher in the first place. Further research needs to assess whether the relative benefit of inpatient care early on, and for those with higher severity is generalizable to lower-cost, nonmedical residential treatment facilities.
A number of additional qualifications and limitations should be noted with regard to the current findings. First, this study compared an initial period of inpatient treatment followed by continuing outpatient care only, as did Rychtarik et al. (2000) . So, it was not a "pure" inpatient versus outpatient comparison. Yet, the design reflects current treatment standards in which inpatient treatment is rarely curtailed abruptly, without referral to continuing outpatient care. Second, the AIS measures a broad severity dimension that includes both negative consequences and physical dependency symptoms. It remains unclear whether similar findings would be found using alternate severity measures. Third, the sample represented a relatively small portion of clients presenting for care, and as with other research on treatment settings was likely biased toward greater severity (Rychtarik, McGillicuddy, Connors, & Whitney, 1998) . Hence, study findings may not be generalizable to all clients presenting for AUD treatment. Fourth, only one of six a priori moderation tests (2 Moderators ϫ 3 Primary Outcomes) yielded a significant finding. That the one significant moderation effect replicated a prior finding increases the confidence in its veracity, but it is still possible it resulted from chance. Fifth, due to the use of naturalistic settings in the study, we cannot rule out that between-setting differences in the services offered, or the clustering of participants within the treatment staff and settings accounted for the results obtained. Detailed records of individual services obtained were not recorded. However, both programs had the same treatment philosophy, much of treatment was group-based, and staff from both programs received joint training experiences. Sixth, the results also are tempered by the fact that the Treatment ϫ Alcohol Involvement Severity interaction was observed only on DDD, and not PDA, as found in Rychtarik et al. (2000) , and also not on the newer PPA variable used in the two-part model. Further, while the number of DDD was nearly cut in half from the pretreatment level among high-involved inpatients relative to outpatients, the mean level of the former was still above safe consumption guidelines. Yet, this reduction in daily consumption might still have had a positive health impact.
To summarize, this study found support for (a) the initial but decreasing benefit of inpatient over outpatient care across time and (b) the validity of alcohol involvement as a client placement criterion for determinations of level of care decisions, at least with respect to alcohol consumption rates. Assigned treatment expectancy also moderated setting effects, but additional research is needed before judgments can be made as to its clinical utility.
